Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report specifically addresses the notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) regarding the vesting of conditional share awards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation events.
- Share Price at Vesting: Ordinary Share: £14.55; American Depositary Share (ADS): US$44.03.
- Transaction Date: March 1, 2013.
Material Changes
The material change reported is the completion of the three-year vesting period for awards made in 2010 under the GlaxoSmithKline Share Value Plan (SVP). These awards were conditional on continued employment.
Management Commentary and Unusual Items
Management confirmed that the vesting period for the 2010 SVP awards, which commenced on February 23, 2010, has ended. The notification was issued in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c). No other risks, contingencies, or unusual financial items were disclosed in this specific filing.
Important Facts for Investors to Verify
- Vesting Details: Verify the specific number of ADS and Ordinary Shares vested for connected persons of Mr. P Thomson (837 ADS) and Dr. M Slaoui (640 ADS).
- Executive Status: Confirm that Dr. M Slaoui is identified as an Executive Director.
- Valuation Timing: Note that fair market values were calculated specifically at the point of vesting on March 1, 2013.
- Scope Limitation: Acknowledge that this filing contains no operational or financial performance data for the quarter.